Zobrazeno 1 - 10
of 624
pro vyhledávání: '"autoimmune haemolytic anaemia"'
Autor:
Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Jun-ichi Nishimura, Josephine M.I. Vos, Joan Cid, Michael Storek, Nancy Wong, Ronnie Yoo, Deepthi Jayawardene, Shruti Srivastava, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M. Broome
Publikováno v:
EClinicalMedicine, Vol 74, Iss , Pp 102733- (2024)
Summary: Background: Cold agglutinin disease (CAD) is a rare autoimmune haemolytic anaemia mediated by the classical complement pathway (CP). Sutimlimab selectively targets complement C1s inhibiting classical CP activation. In CADENZA Part A (26-week
Externí odkaz:
https://doaj.org/article/3d87b23487004a108e8a911cd7c2cb67
Publikováno v:
Journal of Family Medicine and Primary Care, Vol 13, Iss 2, Pp 409-416 (2024)
Autoimmune haemolytic anaemia (AIHA) is an acquired heterogenous clinical entity with variable presentations like acute haemolysis or mild, chronic haemolysis compounded with acute exacerbation in winters or fatal uncompensated haemolysis. A step-wis
Externí odkaz:
https://doaj.org/article/0205bd41faea4ec580cdfcf06c885a79
Publikováno v:
Annals of Medicine, Vol 55, Iss 2 (2023)
AbstractBackground Some patients with warm autoimmune haemolytic anaemia (wAIHA) or Evans syndrome (ES) have no response to glucocorticoid or relapse. Recent studies found that sirolimus was effective in autoimmune cytopenia with a low relapse rate.M
Externí odkaz:
https://doaj.org/article/e01a975ad90b4c0bb9657771357054ed
Publikováno v:
Asian Journal of Internal Medicine, Vol 2, Iss 2 (2023)
Autoimmune haemolytic anaemia (AIHA) is a condition characterised by antibody mediated haemolysis. COVID-19 infection has been associated with multiple extra pulmonary complications of autoimmune origin, including AIHA. We report a case of a 72-year-
Externí odkaz:
https://doaj.org/article/df4e9cfaa6e84edc9703fe64d7eef935
Autor:
Eduardo Terán Brage, Marta Fonseca Santos, Rebeca Lozano Mejorada, Rocío García Domínguez, Alejandro Olivares Hernández, Arantzazu Amores Martín, Rosario Vidal Tocino, Emilio Fonseca Sánchez
Publikováno v:
Case Reports in Oncology, Vol 15, Iss 2, Pp 507-514 (2022)
Autoimmune haemolytic anaemia (AIHA) is an acquired disorder in which antibodies are produced against self-erythrocyte antigens. We distinguish those produced by cold antibodies (IgM), which may be associated with lymphoproliferative syndromes, infec
Externí odkaz:
https://doaj.org/article/c814e45ec3b2410d88ee9078642e6c9c
Publikováno v:
Current Medicine Research and Practice, Vol 12, Iss 4, Pp 183-187 (2022)
Cold agglutinin disease, commonly affecting females in the their seventh decade of life, is otherwise a rare entity and has an incidence of one case per million people per year. Cold reactive antibody is associated with autoimmune haemolytic anaemia
Externí odkaz:
https://doaj.org/article/f601a093587d4669933e4ab371692fbe
Autor:
Esther CW deBoer, Astrid JF Thielen, Jeroen D Langereis, Angela Kamp, Mieke C Brouwer, Nienke Oskam, Marlieke L Jongsma, April J Baral, Robbert M Spaapen, Sacha Zeerleder, Gestur Vidarsson, Theo Rispens, Diana Wouters, Richard B Pouw, Ilse Jongerius
Publikováno v:
Clinical & Translational Immunology, Vol 12, Iss 1, Pp n/a-n/a (2023)
Abstract Objectives The complement system is an important component of innate immunity. The alternative pathway (AP) amplification loop is considered an essential feed forward mechanism for complement activation. However, the role of the AP in classi
Externí odkaz:
https://doaj.org/article/f6250e5b1dc740bdaebae56b5cf8eb40
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 3, Pp 1289-1294 (2021)
Autoimmune haemolytic anaemia (AIHA) is a rare immune-related adverse event and appears to be more common with anti-PD1/PDL1 than anti-CTLA4. Little is known about the safety of re-treating with anti-PD1/PDL1 or changing to anti-CTLA4. We present a c
Externí odkaz:
https://doaj.org/article/04e043ef3acc461e8ecaf4d8bc5482aa